The National Pharmaceutical Authority has ordered the withdrawal from the market of Pneumorel syrup and tablets for the treatment of respiratory tract infections after identifying potentially detrimental effects on heart rhythm.
In a note available on the website, Infarmed identified the withdrawal from the market of medicines Pneumorel, syrup, 2mg / ml and Pneumorel retard, gastro-resistant tablets, 80mg.
Infarmed specifies that the Laboratory Portugal – Especialidades Farmacêuticas, Lda, has decided to stop and withdraw these medicines from the market due to identifying a potentially harmful effect on the heart rate associated with the use of drugs containing the substance fenspiride.
These drugs are shown in the treatment respiratory ailments such as rhinopharyngitis, laryngitis, allergy and otolaryngological manifestations of allergy, otitis and sinusitis and lower respiratory tract infections such as rhinotracheobronchitis, bronchitis, chronic bronchitis with or without chronic respiratory insufficiency.
Drugs are also used for respiratory flu and eventually asthmatic background treatment for pure or complex asthma.
That's why Infarmed informed this doctors should not prescribe these medicines pharmacists should not reject them and continue with his return.
Patients recommend Infarmed discontinuation of treatment and returning the packaging to pharmacies for destruction.
"At the same time, they should consult their physician to prescribe a therapeutic alternative if necessary," Infarmed reported.